Is MOTS-c Legal in Pennsylvania?

HealthRX.com

MOTS-c is unapproved and on no FDA bulks list

Print or save as PDF

See the public record for MOTS-c

  • FDA approval / None; MOTS-c is not a component of any approved drug [1]
  • FDA bulks lists / Not on the pharmacy list or the outsourcing-facility list [2][3][8]
  • FDA interim categories / In the nominated-but-withdrawn table, outside all three categories [9]
  • Pennsylvania oversight / Pharmacy and medicine boards assess licensees case by case against professional standards [6][7]
  • Advisory committee / Voted in favor of listing on July 23, 2026; advice only [10][4]
  • HHS draft policy / Names MOTS-c acetate; discretionary, not an approval [4][5]
  • Human data / FDA found no published study in which MOTS-c was given to a person [1]
  • Sport / Prohibited at all times by WADA, S4.4.1 [11]

The short answer for Pennsylvania

MOTS-c has no USP or NF monograph, is not a component of an FDA-approved drug, and is not on FDA's pharmacy bulks list, so it does not meet the federal conditions for compounding from bulk [1][2][8]. A separate draft HHS policy proposes limited enforcement discretion for MOTS-c acetate when specified conditions are met [4][5]. FDA's July 2026 review also found no listing in the European or Japanese pharmacopeias and no product authorized by the European Medicines Agency [1]. MOTS-c appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is absent from FDA's separate list for outsourcing facilities [2][3][8].

In Pennsylvania, the State Board of Pharmacy regulates pharmacies, pharmacists and pharmacy technicians, and its stated role is to decide case by case whether a licensee engaged in unprofessional conduct by departing from an ethical or quality standard of the profession [6]. The State Board of Medicine describes the same case-by-case role for the professionals it regulates, including physicians [7].

What federal law says about a MOTS-c prescription

A state-licensed pharmacy may compound from a bulk substance only if the substance complies with an applicable USP or NF monograph, is a component of an FDA-approved drug product, or appears on FDA's list of bulk substances that can be used in compounding [8]. MOTS-c meets none of those conditions [1][2][8].

MOTS-c also sits in the "nominated but withdrawn" table on FDA's page about bulk substances that may present significant safety risks; that table holds substances previously in category 2 whose nominators withdrew them [9]. FDA's stated concerns are that it has not identified any human exposure data for MOTS-c products by any route, that important safety information is lacking, and that injectable peptides may pose immunogenicity risk from aggregation and impurities [9]. Removal from category 2 was not a finding that the substance is safe [9]. No outsourcing facility reported compounding MOTS-c between January 2017 and December 2025 [1].

The July 2026 advisory committee vote

FDA's Pharmacy Compounding Advisory Committee took up MOTS-c free base and MOTS-c acetate on July 23, 2026; the uses FDA evaluated were obesity and osteoporosis [10]. The committee voted in favor of adding it to the bulks list, against FDA staff's recommendation [4]. That vote is advice only and not binding; MOTS-c is not on the list, and adding it requires formal rulemaking [4].

FDA staff had proposed that neither the free base nor the acetate be added. Their reasons: the substance is not well characterized (inconsistent naming, no impurity, aggregate or endotoxin data), its use in compounding is unknown, there are no animal toxicity studies, and FDA-approved treatments already exist for obesity and osteoporosis, two of the nominated uses [1]. The nominated products were 5 mg and 10 mg subcutaneous injections [1].

The October 2026 HHS draft policy, and what it does not do

HHS filed a draft enforcement-discretion policy for certain compounded peptides on October 28, 2026 (Federal Register document 2026-22192), scheduled for publication October 30, 2026, with comments due two weeks after publication [4]. It names MOTS-c among six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) and covers MOTS-c acetate given by subcutaneous or intramuscular injection [4][5].

Under the draft, HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with the peptide if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading "This is a compounded drug product. Not for resale." [4][5].

The notice says the policy "does not establish any rights for any person and is not binding on HHS or the public," and HHS may revisit it if a safety signal or product quality issue arises [4]. It is not an FDA approval and does not place MOTS-c on any list [4].

What is actually known about MOTS-c in people

FDA found no published study in which MOTS-c, compounded or not, was given to a human; the 12 papers the nominator cited were not clinical studies [1]. The peptide is sold on websites alone and in combinations, including an IV cocktail offered by a wellness clinic, for metabolism, weight loss, glucose control, performance and anti-aging [1].

The pharmacology comes from cells and rodents. In the 2015 discovery paper, Lee and colleagues described a 16-amino-acid peptide encoded in mitochondrial DNA; in mice, treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the main target and AMPK activated [12]. In a 2021 Nature Communications study, MOTS-c improved physical performance in young, middle-aged and old mice, and late-life intermittent treatment increased physical capacity and healthspan; in humans that study showed exercise raises the body's own MOTS-c in muscle and circulation, and nobody was given the peptide [13]. A separate randomized trial of 30 healthy adults found circulating humanin rose after endurance exercise while MOTS-c showed only a trend to increase, and plasma MOTS-c was not related to fitness [14].

On safety, FDA's adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports [1]. FDA found no pharmacokinetic data in humans or live animals; the only kinetic observation is rapid breakdown in human blood in vitro, which raises the question of whether injection can produce active levels [1]. There is no approved dose and no human dosing study [1]. With no animal toxicity studies either, safety in people is unknown, and the agency's stated concern for the injectable form is immunogenicity from aggregation and peptide-related impurities [1][9].

Sport: WADA prohibits it

WADA's Prohibited List names MOTS-c in S4.4.1 among activators of AMP-activated protein kinase. It is prohibited at all times, in and out of competition, and S4.4 substances are non-Specified Substances [11]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [11][15]. FDA notes it was already on the 2024 List [1].

What this means for someone in Pennsylvania

A prescription does not change the federal position. A patient-specific prescription is one condition of the draft HHS policy; it is not one of the routes that lets a pharmacy use a bulk substance under federal law [8][4]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [4]. For a Pennsylvania resident the picture is a peptide that is not approved and not on either bulks list, covered only by a draft enforcement-discretion policy, with Pennsylvania's pharmacy and medicine boards assessing licensees case by case [1][2][3][4][6][7].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, which condition lets a state-licensed pharmacy compound from a bulk substance?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is MOTS-c legal in Pennsylvania?
Pennsylvania's pharmacy and medicine boards regulate their licensees and decide case by case whether conduct departs from a professional standard [6][7]. On the federal side MOTS-c is not FDA-approved, has no USP or NF monograph, and is on neither bulks list [1][2][3][8], while a draft HHS policy names MOTS-c acetate for limited enforcement discretion if its conditions are met [4][5].
Is MOTS-c FDA-approved?
No. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, no EMA-authorized product, and no approved drug that contains MOTS-c [1].
Did an FDA committee vote to approve or list MOTS-c?
The Pharmacy Compounding Advisory Committee voted in favor of adding MOTS-c to the bulks list on July 23, 2026, against FDA staff's recommendation [10][4]. MOTS-c is not on the list, and listing requires formal rulemaking [4].
Does the HHS peptide policy make MOTS-c legal?
No. The October 2026 HHS policy is a draft that says HHS does not intend to take enforcement action against certain pharmacies and physicians if conditions are met, and it states that it establishes no rights [4][5]. It is not an approval and does not put MOTS-c on any list [4].
Has MOTS-c been tested in people?
Not as an administered drug, according to FDA's search [1]. The human studies that exist measured the body's own MOTS-c after exercise, and nobody in them was given the peptide [13][14].
Is MOTS-c banned in sport?
Yes. WADA names MOTS-c in S4.4.1 as an AMPK activator, prohibited at all times in and out of competition, and it stays on the 2027 Prohibited List [11][15].
Show all 15 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Official web page.
  5. Official web page.
  6. Pharmacy | Department of State | Commonwealth of Pennsylvania.
  7. Medicine | Department of State | Commonwealth of Pennsylvania.
  8. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  10. U.S. Food and Drug Administration.
  11. World Anti-Doping Agency.
  12. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  13. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  14. von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
  15. World Anti-Doping Agency.
Evidence overview for Is MOTS-c Legal in Pennsylvania?